Condition: Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy · Sponsor: University Hospital, Rouen
The aim of the study is to evaluate the prevalence of positive anti BP180 and/or anti BP230 serology in the serum of patients with chronic and diffuse pruritus for at least 1 month under immunotherapy and in the absence of obvious pruritic dermatosis (e.g. scabies, contact eczema...).
This description comes directly from the study's public registry record.
Vivien HEBERT, MD · 02 32 88 · vivien.hebert@chu-rouen.fr
Armelle GUIDOTTI · 023288 · armelle.guidotti@chu-rouen.fr
Always discuss trial participation with your own doctor first.
| UHRouen | Rouen, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05689463